278 related articles for article (PubMed ID: 10458149)
1. US acts to lengthen term of patents to help biotechnology.
Wadman M
Nature; 1999 Aug; 400(6745):604. PubMed ID: 10458149
[No Abstract] [Full Text] [Related]
2. Patent reform acts ugly.
Nat Biotechnol; 2007 Nov; 25(11):1187. PubMed ID: 17989652
[TBL] [Abstract][Full Text] [Related]
3. US Supreme Court applies strict limits to patents.
Robertson D
Nat Biotechnol; 2002 Jul; 20(7):639. PubMed ID: 12089532
[No Abstract] [Full Text] [Related]
4. US Supreme Court decision could compromise biotech patents.
Robertson D
Nat Biotechnol; 2001 May; 19(5):394. PubMed ID: 11328981
[No Abstract] [Full Text] [Related]
5. Genomics companies welcome US PTO initiative on DNA patents.
Marshall A
Nat Biotechnol; 1997 Feb; 15(2):121-2. PubMed ID: 9035129
[No Abstract] [Full Text] [Related]
6. Surprise US election results may boost biotech.
Fox JL
Nat Biotechnol; 2002 Dec; 20(12):1176. PubMed ID: 12454655
[No Abstract] [Full Text] [Related]
7. Equivalents in biotechnology patents.
Auer HE
Nat Biotechnol; 2003 Mar; 21(3):329-31. PubMed ID: 12610574
[No Abstract] [Full Text] [Related]
8. "Ganske" threatens biotechnology patents worldwide.
Glaser V
Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
[No Abstract] [Full Text] [Related]
9. The 1992 biotechnology agenda: a message for candidates Bush and Clinton.
Duzan SA
Healthspan; 1992 Sep; 9(8):12-5. PubMed ID: 10122052
[No Abstract] [Full Text] [Related]
10. Patents, biotechnology, and hematologic pathology.
Kettelberger DM; Gambrell P; McClung G
Hematol Pathol; 1992; 6(2):99-104. PubMed ID: 1607346
[No Abstract] [Full Text] [Related]
11. Biotechnology patents: strategies for meeting economic and ethical concerns.
Gold ER
Nat Genet; 2002 Apr; 30(4):359. PubMed ID: 11925560
[No Abstract] [Full Text] [Related]
12. Ordering life: law and the normalization of biotechnology.
Jasanoff S
Not Polit; 2001; 17(62):34-50. PubMed ID: 15468485
[No Abstract] [Full Text] [Related]
13. US to rule on research patent.
Ruttimann J
Nature; 2006 Mar; 440(7084):587. PubMed ID: 16572133
[No Abstract] [Full Text] [Related]
14. Biotech patents and the inequitable conduct doctrine.
Michael A
Nat Biotechnol; 2006 Oct; 24(10):1219-21. PubMed ID: 17033655
[No Abstract] [Full Text] [Related]
15. The coming US patent opposition.
Apple T
Nat Biotechnol; 2005 Feb; 23(2):245-7. PubMed ID: 15696151
[No Abstract] [Full Text] [Related]
16. Inter partes reexamination: a potentially useful approach to challenging invalid biotechnology patents.
Derzko NM; Behringer JW
Nat Biotechnol; 2003 Jul; 21(7):823-5. PubMed ID: 12833101
[No Abstract] [Full Text] [Related]
17. Biotech patents: looking backward while moving forward.
Eisenberg RS
Nat Biotechnol; 2006 Mar; 24(3):317-9. PubMed ID: 16525404
[No Abstract] [Full Text] [Related]
18. Procedure for gene patents.
Blecher M
Nature; 1993 Jan; 361(6409):199. PubMed ID: 8423844
[No Abstract] [Full Text] [Related]
19. Recent US patent legislation: what's new for biotech?
Gogoris AC; Todaro JC
Nat Biotechnol; 2000 Feb; 18(2):229-31. PubMed ID: 10657135
[TBL] [Abstract][Full Text] [Related]
20. Beyond the letter of the law: the US Federal Circuit interprets section 271(g)(1).
Tsao R; Hurley EA
Nat Biotechnol; 1997 Jan; 15(1):86-7. PubMed ID: 9035112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
